Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Share-based Compensation: 2015-2024

Historic Share-based Compensation for Apellis Pharmaceuticals (APLS) over the last 10 years, with Dec 2024 value amounting to $114.1 million.

  • Apellis Pharmaceuticals' Share-based Compensation rose 2.59% to $28.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.1 million, marking a year-over-year decrease of 4.35%. This contributed to the annual value of $114.1 million for FY2024, which is 7.72% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Share-based Compensation of $114.1 million as of FY2024, which was up 7.72% from $105.9 million recorded in FY2023.
  • Apellis Pharmaceuticals' 5-year Share-based Compensation high stood at $114.1 million for FY2024, and its period low was $45.4 million during FY2020.
  • For the 3-year period, Apellis Pharmaceuticals' Share-based Compensation averaged around $103.7 million, with its median value being $105.9 million (2023).
  • Data for Apellis Pharmaceuticals' Share-based Compensation shows a peak YoY surged of 114.60% (in 2020) over the last 5 years.
  • Apellis Pharmaceuticals' Share-based Compensation (Yearly) stood at $45.4 million in 2020, then skyrocketed by 55.74% to $70.7 million in 2021, then grew by 28.89% to $91.1 million in 2022, then increased by 16.31% to $105.9 million in 2023, then increased by 7.72% to $114.1 million in 2024.